Compare Berkshire Hathaway Inc Class B (BRK.B) vs TG Therapeutics Inc (TGTX) Price & Performance

Berkshire Hathaway Class B shares (BRK.B) trade at $516.22, down 2.54% today, with a bullish technical signal driven by moving averages. Analyst consensus is positive with 57% buy ratings. The stock shows strong technical momentum with key support at $513 and resistance at $522.

The outlook remains favorable given strong institutional support and bullish technicals, though risks include market volatility and economic sensitivity. Upside potential hinges on continued earnings stability and strategic acquisitions under Warren Buffett's leadership.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.